Bicara Therapeutics (BCAX) to Release Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Bicara Therapeutics Price Performance

Shares of BCAX stock opened at $13.00 on Monday. The firm’s 50 day moving average is $14.40. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

Analysts Set New Price Targets

BCAX has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright boosted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. Finally, RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.